Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH925 in KRAS G12C-mutated advanced solid tumors
NCT05005234Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulzerasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Innovent Biologics. Started Sep 2021; status: completed.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05005234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005234.